呼吸道感染的疾病负担分析与实验室检测技术的研究进展

牛 树敏, 代 娣, 夏 楠*
中国医科大学附属第一医院检验科

摘要


呼吸道感染（Respiratory Infections，RI）是全球高发病、高致死性疾病，儿童、老年人及免疫功能低下人群负担尤重，属公共卫生重点关注议题。本文系统综述其流行病学特征、病原谱及耐药性变迁，拟为科学研究与临床诊疗提供数据支撑；实验室检测层面，重点剖析传统检测局限与突破，探讨新兴检测技术的应用与前景，人工智能、大数据及新型检测技术正推动RI诊疗精准化、智能化。未来，需聚焦创新检测技术研发、多靶点治疗探索及免疫调节与个体化治疗研究，提升RI诊疗与防控能力，对降低发病率、减轻全球疾病负担至关重要。

关键词


呼吸道感染；疾病负担；病原体分布；实验室检测；防控策略

全文:

PDF


参考


[1]Global Health Estimates: Life expectancy and leading causes of death and disability[EB/OL].[2025-03-05].https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates.

[2]Bender RG, Sirota SB, Swetschinski LR, et al. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021[J/OL]. Lancet Infect Dis, 2024: S1473309924001762.

[3]Li M, Song Z, Wan W, et al. Burden of non-COVID-19 lower respiratory infections in China (1990-2021): a global burden of disease study analysis[J]. Respir Res, 2025, 26(1): 125.

[4]Zhang Y, Yuan L, Zhang Y, et al. Burden of respiratory syncytial virus infections in China: systematic review and meta-analysis[J]. J Glob Health, 2015.

[5]Zhang J, Yang T, Zou M, et al. The epidemiological features of respiratory tract infection using the multiplex panels detection during COVID-19 pandemic in Shandong province, China[J]. Sci Rep, 2023.

[6]Grech AK, Foo CT, Paul E, et al. Epidemiological trends of respiratory tract pathogens detected via mPCR in Australian adult patients before COVID-19[J]. BMC Infect Dis, 2024.

[7]中华医学会儿科分会呼吸学组，重庆市妇幼卫生学会儿童健康专委会，中国医药卫生文化协会疫苗与健康分会.中国儿童呼吸道合胞病毒感染防控的专家倡议（2023）[J].中华医学杂志，2023，103（40）：3155-3159.

[8]Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Infect Dis, 2018.

[9]Zumla A, Al-Tawfiq JA, Enne VI, et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections--needs, advances, and future prospects[J]. Lancet Infect Dis, 2014.

[10]Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens[J]. Int J Antimicrob Agents, 2007.

[11]Mlynarczyk G, Mlynarczyk A, Jeljaszewicz J. Epidemiological aspects of antibiotic resistance in respiratory pathogens[J]. Int J Antimicrob Agents, 2001.

[12]Li Y, Liang E, Gao Y. Modeling and simulation of distribution and drug resistance of major pathogens in patients with respiratory system infections[J]. BMC Infect Dis, 2025.

[13]Xu J, Liu J, Li X, et al. Burden of bacterial antimicrobial resistance in China: a systematic analysis from 1990 to 2021 and projections to 2050[J]. J Adv Res, 2025.

[14]Du H, Li J, Wen H, et al. Respiratory pathogen profiles of patients - Beijing Municipality, China, November 2023-April 2024[J]. China CDC Wkly, 2025.

[15]王娜，李海，宋晶晶，等.人呼吸道合胞病毒检测方法的研究进展[J.中华预防医学杂志，2024，58（8）：1143-1149.

[16]Liu Q, Jin X, Cheng J, et al. Advances in the application of molecular diagnostic techniques for the detection of infectious disease pathogens (Review)[J]. Mol Med Rep, 2023.

[17]Finch RG. Epidemiological features and chemotherapy of community-acquired respiratory tract infections[J]. J Antimicrob Chemother, 1990.

[18]马鹏程，陈愉.呼吸道病原体检测方法研究进展[J].中国感染与化疗杂志，2024，24（01）：118-122.

[19]Calderaro A, Buttrini M, Farina B, et al. Respiratory tract infections and laboratory diagnostic methods: a review with a focus on syndromic panel-based assays[J]. Microorganisms, 2022.


Refbacks

  • 当前没有refback。